Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Solid Tumors Harboring MAPK Pathway Alterations”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Early research (Phase 1)Ended earlyNCT02711345
What this trial is testing

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

Who this might be right for
Ovarian NeoplasmsNon-Small-Cell Lung CarcinomaMelanoma+1 more
Novartis Pharmaceuticals 65
Early research (Phase 1)Ended earlyNCT02607813
What this trial is testing

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

Who this might be right for
NSCLCOvarian CancerMelanoma+1 more
Novartis Pharmaceuticals 142
Early research (Phase 1)Active Not RecruitingNCT05557045
What this trial is testing

JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

Who this might be right for
Advanced CancerMetastatic CancerSolid Tumor+4 more
Jazz Pharmaceuticals 98
Early research (Phase 1)UnknownNCT05488821
What this trial is testing

Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.

Who this might be right for
Advanced Solid Tumors Harboring MAPK Pathway Alterations
Qilu Pharmaceutical Co., Ltd. 40